{"name":"Akebia Therapeutics","slug":"akebia-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":62359000,"netIncome":-5345000,"cash":184844000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2015"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"vadadustat test tablets","genericName":"vadadustat test tablets","slug":"vadadustat-test-tablets","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"vadadustat test tablets","genericName":"vadadustat test tablets","slug":"vadadustat-test-tablets","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOaG04aHVtUTdxdWJFS1d5X183SndseDEzZjduUjBlU0N3cXloUFlhRU9XYjF6eUVTTVpFc1JCYzFBS05iSUVuQ2c2RlN1eGhpbi1NYlRDWWZRT3JoTkVpOEJpOUVVRTdXWnF6NVBOYnVmWXlkRDBPMElWM1FLb2FWU21oa0ZtYkVCYzA4N0haZklUNGR2NDM4RDRsVkJJaUtWOGpXNkFvM3V0dS13UFgteTZ1MmdpbWs3YWlPVkFmVGQ?oc=5","date":"2026-04-01","type":"pipeline","source":"Stock Titan","summary":"Akebia brings in ex-Shire R&D chief as it weighs rare kidney assets - Stock Titan","headline":"Akebia brings in ex-Shire R&D chief as it weighs rare kidney assets","sentiment":"neutral"},{"date":"2026-04-01","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-16","type":"pipeline","source":"simplywall.st","summary":"In the wake of Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) latest US$48m market cap drop, institutional owners may be forced to take severe actions - simplywall.st","headline":"In the wake of Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) latest US$48m market cap drop, institutional owners may be forc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPMElCaXVtNWl5S1BtNy13NElyMWRqSzF0SUFBZHBpOHM2MUhIV0F2UGhCSDJYZWVpVC1iN3VTbURwa2Rtc3VjelYtNmxFQmhEeWYzX0tKTFNRU1VmRlZNSDB6bldQSTFLQ2NFbVVkbUE1cGY3WFFVU1UxYVZSNlA0MFBnZFRWTkc5VHNPQTVFRmh6aVdabTZhYmN2TUxUWjRRSVY0WGh0U3Q4TDZQcDZZWmhMbw?oc=5","date":"2025-12-01","type":"earnings","source":"Fierce Biotech","summary":"Akebia to pay $12M to Q32 Bio for centerpiece of rare kidney disease pipeline - Fierce Biotech","headline":"Akebia to pay $12M to Q32 Bio for centerpiece of rare kidney disease pipeline","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-04","type":"earnings","source":"simplywall.st","summary":"Revenues Working Against Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Following 25% Dive - simplywall.st","headline":"Revenues Working Against Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Following 25% Dive","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPNk0wX3REamxjbXZmbHNvckkxZ3VqcmlXUWNiZGg4Mk5CVHJVMkI4bnBPSzJ3QlRnVzJDMDJXNm91d19SYzFMVXk3T3hVd2dJN05mVHRWaEtDdHhWQi1ab2NLbGNEdXo5VUJHdmhEa19wNlRoUW1sZTNDamJfSDJBd3hCMFpPX1VxZ2FHMEc1UUZpUjA?oc=5","date":"2025-10-29","type":"regulatory","source":"Fierce Pharma","summary":"Akebia scraps plan for Vafseo trial after discussions with FDA - Fierce Pharma","headline":"Akebia scraps plan for Vafseo trial after discussions with FDA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNR0tEaVJWczFMSFlyYXRVeTRGbWhqWVU1SVlKXzZlQi1JR1UwczZXZ2hMamlXenpiVWZETkhZd0dfMUh4VnJKbkF0YlZQT213anRISmVMd1hoSkc1SG80N1NIaVo3elpqbmhaUDFTZVNKUFVhQ1F0Y242SkRpSXgyWjVNSVR6X0xoR1R6al80UmN5ZEo1X2pxblZ0QzRwZnFGRzR1bTlTRThIQQ?oc=5","date":"2025-10-29","type":"regulatory","source":"The Pharma Letter","summary":"FDA setback prompts Akebia to give up on broader Vafseo label - The Pharma Letter","headline":"FDA setback prompts Akebia to give up on broader Vafseo label","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5xVVNCcnd1cmNoamFpYmpxYkU5aHlLaVE4a1o2Z0xxTFRwV0JwUDZTTXV6MVBuakZGQXFwNF9HSThtaWxuRmppendoWXRCOVRIT2Rj?oc=5","date":"2025-10-28","type":"regulatory","source":"FirstWord Pharma","summary":"Akebia ditches plans for Vafseo label expansion - FirstWord Pharma","headline":"Akebia ditches plans for Vafseo label expansion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNOXdtUTFjMDdzc09wSXd0VVBWZWljRks0a0tpMGZWZi1EbV9rV3VERVdOR3RuZHFPY0E1WGpRbmRuNWc0ZlAwTERzLUExOGt6ZnI5MFN2YzdSbWdGUmxUdGlZTnoyTnlGcmFiVXhIalk1NHFQY09wZi05b0NoM2ZESFhwTmlJQ1RuajFMQjExYw?oc=5","date":"2025-10-15","type":"pipeline","source":"Yahoo Finance","summary":"Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics - Yahoo Finance","headline":"Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics an","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-07","type":"earnings","source":"simplywall.st","summary":"Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Profit Outlook - simplywall.st","headline":"Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Profit Outlook","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxORW5YT3BDdDhwZG1kYjI5YWg2NWFsRDcwb21VX3RkbDFwcjZYcXQ4MFFKcEo2Zk5QeGdjd2UzWWo2b0c1NGUyZGFtdUpMMDRIaDVpRjVMRU05dlNtZ2Rja3ZSZVk5ZERoMFZfbUlsZWROZkpQNG9OX0dPN3Y3elhsazNJODl3VUVkbjNDVnFaaERnZ1E?oc=5","date":"2025-07-10","type":"regulatory","source":"The Business Journals","summary":"FDA publishes drug rejection letters for 15 Massachusetts biotechs - The Business Journals","headline":"FDA publishes drug rejection letters for 15 Massachusetts biotechs","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNal9PbE5lakhoZWhSU19YME05QWJKbFFQRW02c00xYkxkcXdva3BmUmthQUhTUzZCMHY5N0Z1aGZ6dEhGWnRoaElySTNnLWdabDBhNzNROUNWRF8weGJKMW5hVlNscHlydXd3R09Bay1GVnh2X0ozQkhpMGNSbnRWV29CR1BxNlpmU2lOV3kyU3BMU3JzVHBjcjhLUmhUOHgweldDdXhOT1hvRVFKT2pYbG9RcUc0X1pt?oc=5","date":"2025-06-04","type":"earnings","source":"Seeking Alpha","summary":"Akebia Therapeutics: Finally Showing Potential, But Wait For Q2 Earnings Before Buying - Seeking Alpha","headline":"Akebia Therapeutics: Finally Showing Potential, But Wait For Q2 Earnings Before Buying","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOYTI0WFd5eDJzWDJhNnVrdDE2S1BYenRVSXpjV3VUelROWWVRYXJSSHBQTXBCc2g4MFhKV3ZRU0dzU1VPZ2s3LTlVTnpfSDJhWjE2UHo5Z1J3YlptcFEzck5aVlFlUjJseTNqWjVBbUFFM29sWnhCbDZJMWVzZnYxamxpUVVSY2lkSk51Z09jeUFyNHZyQk11dQ?oc=5","date":"2020-02-18","type":"regulatory","source":"BioPharma Dive","summary":"Akebia locks down control over partner’s new regulatory fast pass - BioPharma Dive","headline":"Akebia locks down control over partner’s new regulatory fast pass","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2015-12-31","revenueHistory":[{"value":0,"period":"2015-12-31"},{"value":0,"period":"2014-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":62359000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-5345000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":184844000,"cashHistory":[],"totalAssets":376565000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}